Gliclazide protects pancreatic β-cells from damage by hydrogen peroxide

被引:78
作者
Kimoto, K
Suzuki, K [1 ]
Kizaki, T
Hitomi, Y
Ishida, H
Katsuta, H
Itoh, E
Ookawara, T
Suzuki, K [1 ]
Honke, K
Ohno, H
机构
[1] Kyorin Univ, Sch Med, Dept Mol Predict Med & Sport Sci, Mitaka, Tokyo 1818611, Japan
[2] Kyorin Univ, Sch Med, Dept Internal Med 3, Mitaka, Tokyo 1818611, Japan
[3] Hyogo Med Univ, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan
[4] Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan
关键词
gliclazide; diabetes; sulfonylurea; oxidative stress; beta-cells; apoptosis;
D O I
10.1016/S0006-291X(03)00310-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidative stress is induced under diabetic conditions and possibly causes various forms of tissue damage in patients with diabetes. Recently, it has become aware that susceptibility of pancreatic beta-cells to oxidative stress contributes to the progressive deterioration of beta-cell function in type 2 diabetes. A hypoglycemic sulfonylurea, gliclazide, is known to be a general free radical scavenger and its beneficial effects on diabetic complications have been documented. In the present study, we investigated whether gliclazide could protect pancreatic beta-cells from oxidative damage. One hundred and fifty muM hydrogen peroxide reduced viability of mouse MIN6 beta-cells to 29.3%. Addition of 2 muM gliclazide protected MIN6 cells from the cell death induced by H2O2 to 55.9%. Glibenclamide, another widely used sulfonylurea, had no significant effects even at 10 muM. Nuclear chromatin staining analysis revealed that the preserved viability by gliclazide was due to inhibition of apoptosis. Hydrogen peroxide-induced expression of an anti-oxidative gene heme oxygenase-1 and stress genes A20 and p21(CIP1/WAF1), whose induction was suppressed by gliclazide. These results suggest that gliclazide reduces oxidative stress of beta-cells by H2O2 probably due to its radical scavenging activity. Gliclazide may be effective in preventing beta-cells from the toxic action of reactive oxygen species in diabetes. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:112 / 119
页数:8
相关论文
共 37 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]   Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation [J].
Asada, M ;
Yamada, T ;
Ichijo, H ;
Delia, D ;
Miyazono, K ;
Fukumuro, K ;
Mizutani, S .
EMBO JOURNAL, 1999, 18 (05) :1223-1234
[3]   Oxidative damage to DNA in diabetes mellitus [J].
Dandona, P ;
Thusu, K ;
Cook, S ;
Snyder, B ;
Makowski, J ;
Armstrong, D ;
Nicotera, T .
LANCET, 1996, 347 (8999) :444-445
[4]   PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW [J].
DEFRONZO, RA ;
BONADONNA, RC ;
FERRANNINI, E .
DIABETES CARE, 1992, 15 (03) :318-368
[5]   Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL [J].
Desfaits, AC ;
Serri, O ;
Renier, G .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (10) :1150-1156
[6]   Glucose and tolbutamide induce apoptosis in pancreatic β-cells -: A process dependent on intracellular Ca2+ concentration [J].
Efanova, IB ;
Zaitsev, SV ;
Zhivotovsky, B ;
Köhler, M ;
Efendic, S ;
Orrenius, S ;
Berggren, PO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (50) :33501-33507
[7]  
ELISASSON L, 1996, SCIENCE, V271, P813
[8]   A20 inhibits NF-κB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis [J].
Ferran, C ;
Stroka, DM ;
Badrichani, AZ ;
Cooper, JT ;
Wrighton, CJ ;
Soares, M ;
Grey, ST ;
Bach, FH .
BLOOD, 1998, 91 (07) :2249-2258
[9]   A20 inhibits cytokine-induced apoptosis and nuclear factor κB-dependent gene activation in islets [J].
Grey, ST ;
Arvelo, MB ;
Hasenkamp, W ;
Bach, FH ;
Ferran, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1135-1145
[10]   Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program [J].
Hoorens, A ;
VandeCasteele, M ;
Kloppel, G ;
Pipeleers, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1568-1574